ACCUSTEM

Building Better Oncology Tools

# Investor Presentation
# Q3 2025

# DISCLAIMER

This presentation contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. In some cases, you can identify these forward-looking statements by terms such as "anticipate," "believe," "continue," "could," "depends," "estimate," "expects," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short-term and long-term business operations and objectives and financial needs.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward- looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward- looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from those anticipated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this presentation. These forward-looking statements speak only as of the date of this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason.

# COMPANY OVERVIEW

Our mission at AccuStem is to provide proprietary diagnostic tools that address unanswered clinical questions to improve patient outcomes and reduce costs to the healthcare system

AccuStem's capital efficient business model and low debt burden will maximize investor return

Our initial product candidates, the MSC and StemPrintER tests, have been extensively validated and published in top tier scientific journals providing a $6.3B market opportunity

1. Data on file

# ACCUSTEM COMPANY OVERVIEW

**Planned for launch in Q1 2027, our primary product candidate, the MSC test, is intended to support treatment and surveillance planning for the millions of patients diagnosed with lung nodules each year in the US.**

**StemPrintER, has been validated to assess risk of recurrence in patients with breast cancer. With StemPrintER's ability to measure tumor "stemness", we are evaluating its ability to predict the benefit of different surgical and radiological interventions.**

| ASSET | TARGET CANCER MARKET | IP PROTECTION | ANALYTICAL VALIDATION | CLINICAL VALIDATION | LEVEL 1 DATA | US LAB TECH TRANSFER | CLINICAL UTILITY/ HEALTH ECON | CMS COVERAGE |
|---|---|---|---|---|---|---|---|---|
| MSC | Lung Cancer | ✓ | ✓ | ✓ | ✓ | # | | |
| StemPrintER | Breast Cancer | ✓ | * | * | * | # | | |

Commercial Launch

*StemPrintER has analytical validation data from its original laboratory and clinical validation and Level 1 data for prognosis but not prediction of surgical benefit; #US lab tech transfer has been initiated for MSC and StemPrintER

# ACCUSTEM AT A GLANCE

## LUNG CANCER PROGRAM

- In-licensed MSC assay from Istituto Nazionale dei Tumori (INT)
- EU patent approved and US patent pending
- MSC has level one validation data from multiple prospective study cohorts with publications in top tier journals
- $5.5B market opportunity with margins >90%
- Commodity testing will be offered along with MSC to generate additional revenue

## BREAST CANCER/STEMNESS PROGRAM

- In-licensed StemPrintER assay from Istituto Europeo di Oncologia (IEO)
- US and EU patents approved
- StemPrintER has been validated in prospective study cohorts and is published in top tier journals
- Established collaborations with leading US and EU institutions
- $800M market opportunity in breast cancer with >80% margins
- Planning to research stemness across different tumor types

## EFFICIENT CORPORATE EXECUTION

- Proven leadership team with nearly 60 combined years of experience in the oncology diagnostics sector
- Opening research lab to focus on breast and stemness programs
- Planning to expand product offering to additional tumor types as resources permit
- Evaluating collaboration strategies with industry partners
- Forming SAB to support effective product development

# ACCUSTEM LUNG PROGRAM

## LUNG NODULES

- More than 15M patients eligible for LDCT screening (<5% screened today)
- ~1.6M nodules identified annually in the US (>90% are benign)
- LDCT alone provides indeterminate results 80% of the time, leading to unnecessary procedures and increased patient anxiety

## MSC TEST

- 24 miRNAs evaluated
- Indicates risk of cancer with NPV >99%
- Enables patients to confidently avoid unnecessary tests and invasive procedures, reducing patient anxiety

## LUNG CANCER

- ACUT plans to offer products for those patients diagnosed with lung cancer
- >236K new cancers diagnosed annually in the US
- Future products may include both proprietary and commodity testing

## STEMPRINT LUNG (~56K PATIENTS)

- 20 gene test
- May identify risk of recurrence for stage IA-IIA patients with lung cancer

## NGS TESTING (~180K PATIENTS)

- Focused multi-gene panel
- Stage II+ patients
- Informs appropriate systemic therapy

# THE CHALLENGES WITH LUNG CANCER SCREENING AND DIAGNOSIS

**80%**

of LDCT results are indeterminate[1]

**62%**

of patients receiving biopsy as the sole diagnostic procedure were benign[2]

**17%**

of patients sent to CT surveillance have malignant nodules[3]

Current lung cancer risk assessment has led to over- and under-treatment of patients

1. ACCP Guidelines. CHEST,. 2013.; 2. Silvestri GA, et al, Chest. 2018.; 3. PANOPTIC data on file.

# VALIDATION OF MSC IN LUNG CANCER SCREENING




MSC significantly improves the accuracy of LDCT screening for patients at risk of developing lung cancer




MSC+ patients are more than 4 times as likely to have lung cancer as MSC- patients

## Combining LDCT and MSC results in a five-fold reduction in false positive rates versus LDCT alone[3]

1. Pastorino, et al. Annal Oncol. 2022; 2. Boeri, et al. Lancet. 2024; 3. Sozzi, et al. J Clin Oncol. 2014

# MSC INTEGRATION INTO LUNG CANCER DIAGNOSTIC WORKUP PROCESS




ACCP Guidelines: Evaluation of Individuals With Pulmonary Nodules – CHEST May 2013

# ACCUSTEM BREAST CANCER AND STEMNESS PROGRAM

**2M+ new breast cancer diagnoses annually**

- No genomic tests to inform surgical approach, benefit of radiation

**StemPrintER is a novel 20-gene test designed to measure the "stemness" of tumors**

- By evaluating the underlying "stem" biology of tumors, we believe our test will address unanswered clinical questions

**StemPrintER is highly prognostic in patients with ER+/HER2- breast cancer**

- High Risk patients are up to 4x more likely to experience a distant recurrence compared to Low Risk patients[1,2]

**Tumor** | **AccuStem Testing** | **Personalized Care**

**"Understanding the prognosis of a patient's cancer is critical to effective treatment planning and patient counseling."**

-Peter Beitsch, MD

1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022

# THE ROLE OF "STEMNESS" IN CANCER


European Journal of Cancer
Volume 46, Issue 7, May 2010, Pages 1198-1203

Cancer stemness and metastasis: Therapeutic consequences and perspectives

Joana Monteiro, Riccardo Fodde


Article | Open Access | Published: 27 October 2020

**Assessing the prognostic value of stemness-related genes in breast cancer patients**

Wen-Jie Wang, Han Wang, Meng-sen Wang, Yue-Qing Huang, Yu-Yuan Ma, Jie Qi, Jian-Ping Shi & Wei Li

## The cancer stem cell hypothesis is a fundamental concept in cancer biology

- Essentially, all tumors arise from precursor cells that are similar to stem cells; these cancer stem cells are highly adaptable and have the ability to grow indefinitely
- This hypothesis and tumor "stemness" have been widely studied across a multitude of tumor types

## "Stemness" indicates how much a tumor behaves like stem cells

- "High stemness" in tumors is considered a primary rationale for disease recurrence and/or lack of response to chemotherapy and radiation
- Surgery may be the only way to effectively kill cancer stem cells or "high stemness" tumors


**The Role of Cancer Stem Cells in Radiation Resistance**

*Christoph Reinhold Arnold[1*], Julian Mangesius[1], Ira-Ida Skvortsova[1,2] and Ute Ganswindt[1]*


**Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance**

*Sangita Sridharan[1†], Cory M. Howard[1†], Augustus M. C. Tilley[1†], Boopathi Subramaniyan[1†], Amit K. Tiwari[2], Randall J. Ruch[1] and Dayanidhi Raman[1*]*

*While the medical community recognizes the potential utility of measuring tumor "stemness," existing diagnostic approaches have not been able to accurately assess it in patients*

# VALIDATION OF STEMPRINTER IN BREAST CANCER




StemPrintER is highly prognostic for outcomes in early-stage breast cancer




StemPrintER outperformed the market leader- OncotypeDx- in the TransATAC cohort

1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022

# STEMPRINTER INTEGRATION INTO BREAST CANCER TREATMENT PLANNING






**Clinical Questions**

What is the subtype of cancer?
Is patient a candidate for NAC?
How aggressive is the cancer?

Mastectomy vs. lumpectomy?
Sentinel node vs. full axillary dissection?
Radiation treatment?

Adjuvant chemotherapy?
Hormone therapy?

**BREAST CANCER GENOMICS**

ACCUSTEM

ACCUSTEM

Myriad genetics · AGENDIA · EXACT SCIENCES · HOLOGIC · veracyte

# OUR LEADERSHIP TEAM AND APPROACH: A PROVEN TRACK RECORD

## WENDY BLOSSER, CEO

- ✓ 23 years of success building organizations in Oncology and Women's Health
- ✓ Led Oncology Sales at Genzyme Genetics prior to $925M acquisition by Integrated Oncology (ticker: LH)
- ✓ Cytyc leadership prior to $6.2B Hologic acquisition

## JEFF FENSTERER, CSO

- ✓ 20-year track record in diagnostic leadership in a variety of functional roles
- ✓ Extensive experience developing and validating esoteric tests
- ✓ Led extensive product launch/relaunch efforts at Biodesix, Agendia and Precision Therapeutics (PTI)

## JOE FLANAGAN, CBO

- ✓ 15 years of strategic expertise with successful product launches at early-stage diagnostic start ups
- ✓ Drove revenue growth at Biodesix, Agendia, Ambry and PTI by enhancing sales team clinical agility and logistical processes

## KEEREN SHAH, CFO

- ✓ 20 years of experience in controllership, financial planning and analysis and IPO offerings
- ✓ Held variety of finance roles at Visa, Arthur Andersen, BBC Worldwide, Tiziana Life Sciences and Okyo Pharma

ACCUSTEM HOLOGIC The Science of Sure Integrated ONCOLOGY LabCorp Specialty Testing Group HELOMICS THE NEXT GENERATION IN PERSONALIZED HEALTHCARE biodesix Ambry Genetics AGENDIA

# BOARD OF DIRECTORS

## GABRIELE CERRONE

**Executive chairman**

- ✓ Chairman and founder of TIZIANA Life Sciences TLSA and OKYO Pharma
- ✓ Inhibitex sale for $2.5B
- ✓ Prior experience at Synergy, Cardiff Oncology, Gensignia, Rasna, Hepion, and Siga Technologies
- ✓ Co-founded NASDAQ: HEPA, CLSP, RASP, CRDF, SIGA

## WENDY BLOSSER

**Director**

- ✓ 25 years of success launching, relaunching and building organizations in diagnostic, surgical and capital sales, with a focus in Oncology
- ✓ Prior experience at Cytyc (HOLX), Laboratory Corporation of America (Integrated Oncology), Biodesix and Agendia

## JOHN BRANCACCIO

**Director**

- ✓ Over 35 years financial experience in pharmaceuticals, biotechnology and medical devices with over 15 years experience with multiple public companies
- ✓ Management and SEC reporting
- ✓ Private and public fundraising experience

## SEAN MCDONALD

**Director**

- ✓ Experienced technology and healthcare executive who has built multiple companies from startup to over $150M in revenue
- ✓ Founder, President and CEO of Ocugenix
- ✓ Past Director Respironics (PHG), Precision Therapeutics and Aethon

## WILLY SIMON

**Director**

- ✓ Career as an executive in the banking and corporate finance sector
- ✓ Previous work at Kredietbank N.V., Citibank, Generale Bank NL; Past CEO of Fortis Investment Management
- ✓ Past chairman of Bank Oyens & van Eeghen; Chairman of Rasna Therapeutics

inhibitex · SIGA Human BioArmor · HOLOGIC · HEPION PHARMACEUTICALS · citibank · SYNERGY PHARMACEUTICALS · tiziana LIFE SCIENCES · AGENDIA · Integrated ONCOLOGY LabCorp Specialty Testing Group · OCUGENIX · KB KREDIETBANK

## INVESTMENT AND COMPANY HIGHLIGHTS

- ✓ Management team with wide-ranging leadership experience across various functional areas, deep relationships with luminary US institutions and a track record of successful launch/relaunch strategies
- ✓ MSC's level 1 data, published in several top tier journals, positions it well to be the market leader in the $5.5B lung cancer screening space
- ✓ Our novel "stemness" platform combined with a strong foundation of evidence for StemPrintER in breast cancer, including outperformance of current market leader, supports commercialization of an $800M market
- ✓ Our strong body of evidence and capital efficient business model make AccuStem an attractive investment opportunity

# THANK YOU FOR YOUR CONSIDERATION

ACCUSTEM

Info@Accustem.com | AccuStem.com